Authors:
L.A. Shchepanevich1*, M.M. Tanashian2, Yu.A. Nikolaev1, V.Ya. Polyakov1, M.A. Pervuninskaya1, K.V. Antonova2
1FGBNU "Research Institute of Experimental and Clinical Medicine", Novosibirsk, Russia;
2FGBNU "Scientific Center of Neurology", Moscow, Russia
The purpose of the study is to study the influence of Mexidol on the indicators of the lipid spectrum in patients with very high risk of cardiovascular complications (MTR) suffering from type 2 diabetes (SD2).
Material and methods.
Within 3 months, prospective observation of two groups of patients was carried out, the main risk factor for vascular complications in which was SD2. The speed of reaching the target level of blood lipid indicators with standard therapy with statins (1st group) and when supplementing the basic therapy with Mexidol (2nd group) was compared. The determination of lipids in blood serum was carried out by the enzymatic colorimetric method (reagents Boehringer Mannheim, Germany).
Results.
The positive influence of Mexidol, prescribed at the starting stage of statins, on the indicators of lipid spectrum in patients with high and very high risk of MTS, the underlying disease in which was SD2, was noted.
Key words: cardiovascular complications, type 2 diabetes, dyslipidemia, prevention, Mexidol